


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-30. (Canceled).

31. (Currently Amended) A compound of Formula XII



Formula XII

or a pharmaceutically acceptable salt thereof, wherein:

R represents from 0 to 4 substituents independently chosen from fluoro, chloro, hydroxy, C₁-C₆alkoxy, C₁-C₆alkyl, C₁-C₂haloalkyl, and C₁-C₂haloalkoxy;


R¹ and Ar² are independently chosen from:

- (i) phenyl(C₀-C₁alkyl), substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, C₁-C₆alkoxy, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, cyano, amino, nitro, -COOH, carboxamide, mono- and di-(C₁-C₆alkyl)amino, C₁-C₆haloalkyl and C₁-C₆haloalkoxy; and
- (ii) 2-indanyl, substituted with 0, 1 or 2 substituents independently selected from fluoro, chloro, hydroxy, methyl, ethyl, methoxy, ethoxy, mono-, di- and tri-fluoromethyl, and mono-, di- and tri-fluoromethoxy;

R⁴ is hydrogen, C₁-C₆alkyl, C₁-C₂haloalkyl, fluoro or chloro;

R⁷ is hydrogen or C₁-C₆alkyl;

R⁹ represents from 0 to 5 substituents independently chosen from ~~hydrogen~~, halogen, hydroxy, C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆haloalkyl, and C₁-C₆haloalkoxy; and

 represents a single or double bond.

32. (Original) A compound according to claim 31, wherein the compound is:
N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl)-acetamide;
N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(2-o-tolyl-piperidin-1-yl)-acetamide;
N-(2-Fluoro-benzyl)-N-indan-2-yl-2-[2-(2-methoxy-phenyl)-piperidin-1-yl]-acetamide;
N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(2-o-tolyl-piperidin-1-yl)-propionamide.
2-(4,5-Dimethyl-6-phenyl-3,6-dihydro-2H-pyridin-1-yl)-N-(2-fluoro-benzyl)-N-indan-2-yl-
acetamide;
2-(4,5-Dimethyl-6-o-tolyl-3,6-dihydro-2H-pyridin-1-yl)-N-(2-fluoro-benzyl)-N-indan-2-yl-
acetamide;
or a pharmaceutically acceptable salt thereof.

33-37. (Canceled).

38. (Currently Amended) A pharmaceutical composition comprising at least one compound or salt according to ~~Claim 1~~ claim 31, or a prodrug or hydrate thereof, in combination with a physiologically acceptable carrier or excipient.

39-40. (Canceled).

41. (Currently Amended) A method for inhibiting signal-transducing activity of a cellular C5a receptor, comprising contacting a cell expressing a C5a receptor with at least one compound or salt according to ~~Claim 1~~ claim 31, and thereby reducing signal transduction by the C5a receptor.

42. (Original) A method according to Claim 41, wherein the cell is contacted *in vivo* in an animal.

43. (Original) A method according to Claim 42, wherein the animal is a human.

44-45. (canceled).

46. (Currently Amended) A method for treating a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma

comprising administering to the patient a C5a receptor modulatory amount of a compound according to ~~Claim 1~~ claim 31.

47. (Currently Amended) A method for treating a patient suffering from stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury comprising administering to the patient a C5a receptor modulatory amount of a compound according to ~~Claim 1~~ claim 31.

48. (Currently Amended) A method for inhibiting C5a receptor-mediated cellular chemotaxis, comprising contacting mammalian white blood cells with a C5a receptor modulatory amount of a compound or salt according to ~~Claim 1~~ claim 31.

49. (Canceled).

50. (Original) A packaged pharmaceutical preparation, comprising:

- (a) a pharmaceutical composition according to Claim 38 in a container; and
- (b) instructions for using the composition to treat a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma.

51. (Original) A packaged pharmaceutical preparation

- (a) a pharmaceutical composition according to Claim 38 in a container; and
- (b) instructions for using the composition to treat stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury.

52. (Original) A pharmaceutical composition according to Claim 38, wherein the pharmaceutical composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup, or a transdermal patch.

53. (New) A compound or salt according to claim 31, wherein R represents 0 substituents or a methyl substituent.

54. (New) A compound or salt according to claim 31, wherein R¹ is 2-indanyl.

55. (New) A compound or salt according to claim 31, wherein Ar² is benzyl, substituted with a halogen.

56. (New) A compound or salt according to claim 31, wherein R^4 is hydrogen or methyl and R^7 is hydrogen.

57. (New) A compound or salt according to claim 31, wherein R^9 represents 0 substituents or a methyl or methoxy substituent.